Spirulina extract put to the test against long COVID inflammation

NCT ID NCT05524532

Completed Disease control Sponsor: University of Mississippi Medical Center Source: ClinicalTrials.gov ↗

First seen Jul 30, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This Phase 3 trial tests whether Immulina, a dietary supplement made from Spirulina, can lower inflammatory markers in the blood of people with long COVID (PASC). About 100 adults aged 18 to 99 will take either Immulina or a placebo for 12 weeks. Researchers will measure changes in inflammation-related chemicals like IL-6, CRP, and D-dimer, as well as symptoms such as fatigue and sleep quality.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: a highly standardized extract of Spirulina called Immulina
What this could lead to: If it works, this could point toward a natural supplement to ease long COVID symptoms by lowering inflammation.
What could go wrong: This is a relatively small trial, and dietary supplements often show mixed results. The effect may be modest or no better than placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POST-ACUTE COVID-19 SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Inflammation long COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

POST-ACUTE COVID-19 SYNDROME

Contacts and locations

Locations

Louisiana State University

New Orleans, Louisiana, 70112, United States
MaineHealth

Portland, Maine, 04101, United States
Pennington Biomedical Research Center

Baton Rouge, Louisiana, 70808, United States
University of Hawaii

Honolulu, Hawaii, 96813, United States
University of Mississippi Medical Center

Jackson, Mississippi, 39216, United States
University of Nebraska Medical Center

Omaha, Nebraska, 68198, United States
University of Oklahoma

Oklahoma City, Oklahoma, 73104, United States
University of Puerto Rico

San Juan, Puerto Rico, 00935, Puerto Rico
West Virginia University

Morgantown, Virginia, 26506, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.